Effect of Guided Imagery on Anxiety, Depression, and Fatigue in Patients Receiving Hemodialysis

November 14, 2026 updated by: Reva Gündoğan, Adiyaman University

Effect of Guided Imagery on Anxiety, Depression, and Fatigue in Patients Receiving Hemodialysis: A Controlled Trial

This study will evaluate whether a four week guided imagery program, delivered three times per week before hemodialysis, affects anxiety, depression, and fatigue in adults receiving hemodialysis compared with routine care. Measures are planned before the intervention and at the end of week four.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This study evaluates guided imagery as a supportive nursing intervention for adults receiving hemodialysis. It focuses on anxiety, depression, and fatigue during a four-week intervention period.

Study Type

Interventional

Enrollment (Estimated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Reva GÜNDOĞAN, Assistant Professor
  • Phone Number: +905551822097
  • Email: r4a5reva@gmail.com

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

  • Aged 18 years or older
  • No cognitive impairment or history of psychiatric illness
  • Willing and able to communicate
  • Receiving hemodialysis for more than six months
  • No hearing, visual, or speech impairment
  • Voluntary agreement to participate in the study Exclusion Criteria
  • Not receiving regular hemodialysis treatment (dialysis instability)
  • Unwilling to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group

Participants in this group will receive routine hemodialysis care without the guided imagery intervention during the four-week study period.

Experimental: Guided imagery group

Guided imagery: Patients will undergo guided imagery three times a week for four weeks. Thirty minutes before hemodialysis, patients will be asked to assume a comfortable position, close their eyes, and take deep breaths. Depending on their preference, various nature sounds such as ocean waves, chirping forest birds, or falling rain will be played through over-ear headphones. Patients will then be asked to imagine themselves in the location depicted in the sound recording, using their senses of sight, hearing, smell, and touch.

Participants will listen to nature sounds through headphones and be guided to imagine the scenes described by the audio, engaging their senses. The intervention will be delivered three times per week for four weeks, 30 minutes before hemodialysis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hospital Anxiety-Depression Scale-anxiety
Time Frame: Before the application: Follow-up 0 Immediately after the application: Follow-up 1 One month after the application: Follow-up 2

HADS : 0 to 21 scores, higher scores indicate worse outcomes.

Before the application: Follow-up 0 Immediately after the application: Follow-up 1 One month after the application: Follow-up 2
Hospital Anxiety-Depression Scale-depression
Time Frame: Before the application: Follow-up 0 Immediately after the application: Follow-up 1 One month after the application: Follow-up 2

HADS : 0 to 21 scores, higher scores indicate worse outcomes.

Before the application: Follow-up 0 Immediately after the application: Follow-up 1 One month after the application: Follow-up 2

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Piper Fatigue Scale
Time Frame: Before the application: Follow-up 0 Immediately after the application: Follow-up 1 One month after the application: Follow-up 2

PFS: 0 to 230 scores, higher scores indicate worse outcomes.

Before the application: Follow-up 0 Immediately after the application: Follow-up 1 One month after the application: Follow-up 2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

May 15, 2027

Study Registration Dates

First Submitted

October 25, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 14, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • RG-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

It can be provided upon request from researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.